[REVISION HISTORY]
Polish neurology reforms and therapy developments
Updated 1 time since CLSTR started tracking revisions of this situation.
What changed
2026-08-03 10:24 UTC → 2026-08-24 21:33 UTC ·
added
removed
Polish neurology reforms and therapy gaps developments
At a Warsaw drug‑policy drug-policy conference in late July, May, Polish neurologists called for systemic reforms to address a rising burden of dementia and other neurological disorders. They urged Prof. Alina Kułakowska, president of the creation Polish Society of Neurology, warned that an aging population and lifestyle factors are increasing patient numbers, necessitating a clear referral network, better funding and staffing for diagnostic reference network and treatment units, streamlined patient pathways. Prof. Halina Sienkiewicz-Jarosz emphasized the dementia crisis, noting that approximately 600,000 Poles have or are developing dementia, and highlighted argued that the National Programme for Actions against Dementia (2025‑2030). In (2025–2030) requires adequate funding and organizational solutions. By early August, the discussion shifted to discussions highlighted specific treatment shortages, noting that gaps, particularly for multiple sclerosis (MS). While over 20 drugs exist for relapsing-remitting MS, only one disease‑modifying drug is approved for primary‑progressive multiple sclerosis (PPMS) and that access is limited by primary-progressive MS (PPMS), leaving a significant unmet need due to systemic restrictions. The speakers also emphasized broader brain‑health initiatives, promoting lifestyle To combat these risks, experts promoted lifestyle-based prevention—such as managing blood pressure and diet—noting that such measures to lower can reduce dementia risk by up to 45%. More recently, neurologists have advocated for a national strategy including a ‘National Neurological Network’ and underscoring the unmet medical need ‘10 Commandments of Health’ for effective PPMS therapies. Together, the snapshots trace a progression from disease prevention. Amidst these calls for structural health‑system reforms change, medical research in Gdańsk is progressing on an innovative MS therapy. Using the molecule CF₃-7α,25-OHC, researchers aim to concrete concerns about drug availability both reduce inflammation and preventive strategies for Poland’s growing population of patients stimulate myelin repair, moving toward clinical applications with neurological conditions. support from the Czech investment fund LIFE bioCEEd.
Versions
- 2026-08-24 21:33 UTC Polish neurology reforms and therapy developments
- 2026-08-03 10:24 UTC Polish neurology reforms and therapy gaps
Only revisions since CLSTR began indexing content versions appear here. Select a version to see what changed compared to the one before it.